Antiplatelet agents have been utilized to enhance outcomes in patients with acute coronary
syndrome for decades and are increasingly valued for their antithrombotic as well as anti …

Dual antiplatelet therapy is currently recommended for all patients with acute coronary
syndromes, independent of whether they receive pharmacological treatment or undergo …

Thrombus formation is a crucial event in acute coronary syndromes, 1 bypass occlusion, 2
and stent thrombosis. 3 In the coronary circulation, platelet activation is an initial event, 4 …

The use of antiplatelet monotherapy as part of treatment regimens for high-risk patients with
thrombotic disease results in significant reductions in ischaemic outcomes. Numerous …

Dual antiplatelet therapy (DAPT), or the combination of aspirin and an oral inhibitor of the
platelet P2Y12 receptor, is indicated in acute coronary syndromes (ACS) and after …

International guidelines recommend the use of aspirin treatment immediately and
indefinitely in coronary patients. The optimal time to start and the duration of dual antiplatelet …

Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of
thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging …

Background: After acute coronary syndrome, guidelines recommend dual antiplatelet
therapy with aspirin and a P2Y 12 inhibitor for a period of 12 months for the prevention of …

Dual antiplatelet therapy, combining aspirin with a platelet P2Y 12 receptor inhibitor, is the
standard treatment for acute coronary syndrome patients undergoing percutaneous …

Dual antiplatelet therapy based on the combination of an adenosine diphosphate (ADP)-
receptor antagonist plus aspirin has demonstrated to be more effective in reducing the rate …